Shamburg News · 8-K filed Nov 12, 2026, 4:05 PM EST

Prime Medicine Reports Third Quarter 2026 Financial Results and Business Updates

PRME · Prime Medicine, Inc.

  • Earnings
  • Financing
  • Materiality: high

Prime Medicine reported a net loss of $39.0 million for the quarter ended September 30, 2026, compared with $50.6 million a year earlier, on collaboration revenue of $4.2 million. Research and development expenses were $34.1 million and general and administrative expenses were $10.0 million for the quarter. The company reported basic and diluted net loss per share of $0.22 and said its November 2026 public offering raised $143.7 million in gross proceeds.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001628280-26-073372.

Written from the filing by Shamburg Markets. Figures are as reported by the company.